Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)
Sponsor study identifier
observational
220
1 country
1
Study Start
February 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2010
Actual (reported)Study Completion
October 2010
Actual (reported)This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2010
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2010
Date type not reportedThis date has not been verified as actual or estimated.
October 2010
Actual (reported)October 2010
Actual (reported)April 6, 2011
Actual (reported)April 11, 2011
Actual (reported)February 22, 2016
Actual (reported)Median Overall Survival
The time between the first infusion of trastuzumab and the date of death from any cause. Participants who were still alive at the end of the post-HERMINE study or lost to follow-up were censored at the last date they were known to be alive.
Up to 7 years
Median Time to Progression-Free Survival
Up to 7 years
Median Time to Progression
Up to 7 years
Median Treatment Duration and the Duration of Exposure to Trastuzumab
Up to 7 years
Prognostic Factors for Overall Survival
Up to 7 years
Prognostic Factors For Time to Progression
Up to 7 years
metastatic breast cancer patients treated by Herceptin® as 1st line therapy
Neuilly-sur-Seine, 92521, France
Clinical Trials
Hoffmann-La Roche
220 participants (actual enrollment reported by the registry).
First Submitted
April 6, 2011
First Posted
April 11, 2011
Study Start
February 2010
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
October 2010
Actual (reported)Study Completion
October 2010
Actual (reported)Last Updated
February 22, 2016
Results First Posted
February 22, 2016
Record last verified: 2016-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: